Abstract
Cancer is the second leading cause of death both globally and in the United States [1]. Recent studies suggest that the detection of cancer at early, pre-clinical stages has the potential to reduce cancer-specific morbidity and mortality [2]. Yet, at present, more than 70% of cancer deaths occur in organ sites without approved early detection modalities [2] mainly due to cost-ineffectiveness caused by low disease prevalence in most organ sites, combined with the low sensitivity of detection at early stages, and the relatively high false positive rates that can lead to significant morbidities or mortality from unwarranted invasive diagnostic procedures, or to unnecessary financial toxicity. Currently, screening programs for early cancer detection in the general population in the United States are recommended only for a few organ sites with relatively high incidence, including colon, breast, and cervix [3], as well as for lung cancer in individuals with increased, smoking history-based risk [4], or for prostate cancer at an individualized basis [5]. Existing screening programs, such as colonoscopy for colorectal cancers, mammography for breast cancer, or low-dose computed tomography for lung cancer, require expensive infrastructure and highly trained technical and medical personnel. Hence, compliance with recommended screenings has remained poor [6], especially among historically and socioeconomically vulnerable populations, such as ethnic/racial minorities, under-insured or uninsured individuals, or those residing in rural areas with limited access to health care services.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
L. A. Torre, R. L. Siegel, E. M. Ward, A. Jemal, Global Cancer Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol Biomarkers Prev 25, 16-27 (2016).
R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, Cancer Statistics, 2021. CA Cancer J Clin 71, 7-33 (2021).
R. A. Smith et al., Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 69, 184-210 (2019).
I. Toumazis, M. Bastani, S. S. Han, S. K. Plevritis, Risk-Based lung cancer screening: A systematic review. Lung Cancer 147, 154-186 (2020).
W. J. Catalona, Prostate Cancer Screening. Med Clin North Am 102, 199-214 (2018).
I. J. Hall et al., Patterns and Trends in Cancer Screening in the United States. Prev Chronic Dis 15, E97 (2018).
J. C. M. Wan et al., Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17, 223-238 (2017).
Y. M. D. Lo, W. K. J. Lam, Towards multi-cancer screening using liquid biopsies. Nat Rev Clin Oncol 17, 525-526 (2020).
J. D. Cohen et al., Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926-930 (2018).
M. C. Liu et al., Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 31, 745-759 (2020).
D. A. Ahlquist, Universal cancer screening: revolutionary, rational, and realizable. NPJ Precis Oncol 2, 23 (2018).
E. Hubbell, C. A. Clarke, A. M. Aravanis, C. D. Berg, Modeled Reductions in Late-stage Cancer with a Multi-Cancer Early Detection Test. Cancer Epidemiol Biomarkers Prev 30, 460-468 (2021).
G. Siravegna et al., How liquid biopsies can change clinical practice in oncology. Ann Oncol 30, 1580-1590 (2019).
M. Ignatiadis, G. W. Sledge, S. S. Jeffrey, Liquid biopsy enters the clinic – implementation issues and future challenges. Nat Rev Clin Oncol 18, 297-312 (2021).
F. Diehl et al., Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985-990 (2008).
C. Alix-Panabieres, K. Pantel, Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov 6, 479-491 (2016).
L. De Mattos-Arruda et al., Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6, 8839 (2015).
Y. H. Su, A. K. Kim, S. Jain, Liquid biopsies for hepatocellular carcinoma. Transl Res 201, 84-97 (2018).
R. Einoch Amor, M. K. Nakhleh, O. Barash, H. Haick, Breath analysis of cancer in the present and the future. Eur Respir Rev 28, (2019).
X. Chen et al., Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA. Clin Cancer Res 27, 4221-4229 (2021).
W. Qian, Y. Zhang, W. Chen, Capturing Cancer: Emerging Microfluidic Technologies for the Capture and Characterization of Circulating Tumor Cells. Small 11, 3850-3872 (2015).
E. Shumilov et al., Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Crit Rev Oncol Hematol 126, 64-79 (2018).
A. L. Volckmar et al., A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. Genes Chromosomes Cancer 57, 123-139 (2018).
I. W. Deveson et al., Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol 39, 1115-1128 (2021).
J. Kowal, M. Tkach, C. Thery, Biogenesis and secretion of exosomes. Curr Opin Cell Biol 29, 116-125 (2014).
S. Cristiano et al., Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385-389 (2019).
J. P. Hinestrosa et al., Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med (Lond) 2, 29 (2022).
A. M. Lennon et al., Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369, (2020).
P. V. Nuzzo et al., Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med 26, 1041-1043 (2020).
J. J. Kim, E. A. Burger, C. Regan, S. Sy, Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force. JAMA 320, 706-714 (2018).
C. D. Lehman et al., National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology 283, 49-58 (2017).
P. F. Pinsky et al., Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med 162, 485-491 (2015).
L. C. Leiman, J. Baden, K. D’Auria, C. J. Lin, K. Meier, Creating standards for liquid biopsies: the BLOODPAC experience. Expert Rev Mol Diagn, 1-3 (2022).
R. L. Grossman et al., BloodPAC Data Commons for Liquid Biopsy Data. JCO Clin Cancer Inform 5, 479-486 (2021).
P. G. Febbo et al., Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases. Clin Pharmacol Ther 107, 730-734 (2020).
J. H. Godsey et al., Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group. Clin Chem 66, 1156-1166 (2020).
P. M. Williams et al., Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO Precis Oncol 5, (2021).
G. Putcha, A. Gutierrez, S. Skates, Multicancer Screening: One Size Does Not Fit All. JCO Precis Oncol 5, 574-576 (2021).
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patriotis, C., Srivastava, S. (2023). Early Cancer Detection: Challenges and Opportunities. In: Cote, R.J., Lianidou, E. (eds) Circulating Tumor Cells. Current Cancer Research. Springer, Cham. https://doi.org/10.1007/978-3-031-22903-9_24
Download citation
DOI: https://doi.org/10.1007/978-3-031-22903-9_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-22902-2
Online ISBN: 978-3-031-22903-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)